On The Pen GLP-1 News

On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top Substack best-seller.

On The Pen GLP-1 News is a health podcast hosted by Dave Knapp GLP-1 Industry Insider, with 210 episodes on record and a Required Pod Score of 80.

Dave Knapp GLP-1 Industry Insider hosts On The Pen GLP-1 News, a health show with 210 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  On The Pen GLP-1 News

  They TRIPLED Wegovy Dose, Does it Beat Zepbound?

  Sep 30, 202631 min

  This week on On The Pen, The Weekly Dose, we break down one of the biggest weeks in obesity medicine coming out of EASD 2026.Eli Lilly says Zepbound may still outperform Wegovy 7.2 mg, even after Novo Nordisk tripled the familiar maintenance dose, but the details are more complicated than the headline. We dig into the difference between the treatment-regimen and efficacy estimands, and why this was not a true head-to-head trial.We also cover Novo Nordisk’s $2.6 billion bet on a potential once-weekly oral GLP-1/GIP, new Foundayo data against high-dose oral semaglutide, Viatris and Mylan’s renewed patent fight over the future of generic Wegovy, and the full Phase 3 retatrutide publication in the New England Journal of Medicine.Plus, after weeks of concern over GLP-1 medications and NAION-related vision loss, we look at one practical thing patients may be able to do right now to better understand their own baseline risk.This episode is about more than who “wins” between Lilly and Novo. It is about what the data actually says, where the next generation of obesity treatment is headed, and what all of this means for patients trying to make informed decisions with their doctors.Covered in this episode: Zepbound vs. Wegovy 7.2 mg, retatrutide TRIUMPH-1 Phase 3 data, Foundayo/orforglipron, oral semaglutide, once-weekly oral GLP-1s, generic Wegovy patent litigation, NAION, GLP-1 vision risk, EASD 2026, Eli Lilly, Novo Nordisk, Viatris and Mylan.Subscribe for breaking GLP-1, obesity, diabetes and metabolic-health news, explained from the patient perspective.Get Exclusive OTP Savings and Resrouces:Https://www.otplinks.comGet Breaking Obesity Medicine News:HTTPS://www.onthepen.com

  ListenShow Notes
• 

  On The Pen GLP-1 News

  Retatrutide in Court, Compound GLP-1 Under Fire

  Sep 22, 202630 min

  This week on On The Pen, The Weekly Dose Podcast, retatrutide heads into a major federal court fight as the Department of Justice gives FDA fresh legal ammunition just days before oral argument. At the same time, FDA is escalating its scrutiny of mass GLP-1 compounding, with a warning letter to Empower Pharmacy that could have major implications for semaglutide, tirzepatide, telehealth prescribing, and patient access. We also break down Viking Therapeutics’ new VK2735 maintenance data, including early weight-loss numbers that are starting to draw retatrutide comparisons and the possibility of every-other-week or even monthly maintenance dosing. Plus, Roche’s enicepatide, formerly CT-388, just posted a 2.65 percentage-point A1C reduction and 15.5% weight loss in people with type 2 diabetes and obesity, raising new questions about how competitive the next generation of GLP-1/GIP drugs may become. This episode is about more than one drug. It is about where obesity medicine is heading, who gets access, how regulators are drawing the lines, and why the next few years may look very different from the market we know today. Https://www.onthepen.com Https://www.otplinks.com

  ListenShow Notes
• 

  On The Pen GLP-1 News

  17% Weight Loss in 16 Weeks… Is This Better Than Retatrutide?

  Sep 15, 202630 min

  Lilly just gave us a glimpse of what could come after today’s GLP-1s, and it may not be about simply pushing patients to stronger drugs and higher doses. This week on On The Pen: The Weekly Dose, we break down Lilly’s surprising early data combining just 5 mg of tirzepatide with 3 mg of eloralintide, producing roughly 17% weight loss in only 16 weeks. Could combinations like this eventually approach retatrutide-level efficacy with better tolerability? And when retatrutide reaches the real world, how many patients will actually need or tolerate the higher doses responsible for its biggest clinical-trial numbers? We’re also digging into the bigger stories shaping the future of obesity medicine, including new research suggesting semaglutide may influence aging beyond calorie restriction in mice, the emerging race to preserve lean mass during GLP-1 weight loss, apitegromab’s eye-popping price, Lilly’s legal battle over retatrutide’s classification, the underground market already selling unapproved Reta, and the latest development in Lilly’s lawsuit against Mochi. The science is getting better incredibly quickly. The bigger question may be whether we can deliver enough efficacy, tolerability and muscle preservation at a price patients can actually access. Like, comment and subscribe if you want patient-centered GLP-1 news without the pharmaceutical press-release filter. If you listen to the podcast on Apple or Spotify, leaving a rating and review is one of the best ways to help more people find On The Pen. Everything On The Pen: linktr.ee/manonthemounjaro⁠ On The Pen: Empowering you to have better conversations with your doctor. #GLP1 #Zepbound #Mounjaro #Retatrutide #Tirzepatide #Eloralintide #WeightLoss #ObesityMedicine #Ozempic #Wegovy

  ListenShow Notes
• 

  On The Pen GLP-1 News

  GLP-1 for 6 Year Olds? Here’s What the Trial Actually Found

  Sep 8, 202626 min

  Is obesity still a disease worthy of treatment when the patient is six years old? This week, Novo Nordisk released Phase 3 STEP Young data in children ages 6 to 11 with obesity. After 68 weeks, 40.4% of children treated with semaglutide moved below the obesity threshold, compared with 0% on placebo. More than 85% of the children entered the trial with class II or class III severe obesity, and both groups received lifestyle intervention. That raises a harder question than whether people are comfortable with kids taking GLP-1s: compared with what? A nearly 90% chance that obesity present at age 3 persists into the teen years? An approximately 80% chance that a teen with obesity carries it into adulthood? Another decade of stigma, bullying, and metabolic disease while we keep telling families to try harder? I’m unapologetically supportive of studying and treating severe childhood obesity. That does not mean ignoring long-term questions around growth, puberty, nutrition, lean mass, or what happens when treatment stops. It means recognizing that withholding treatment is also a decision with consequences. We also break down the new Structure Therapeutics data, including aleniglipron, an oral small-molecule GLP-1 that produced up to 16.2% mean weight loss at 72 weeks, and ACCG-2671, an experimental oral amylin/calcitonin agonist that produced 3.3% mean weight loss after a single dose, with some important tolerability caveats. Plus, we look at a preliminary semaglutide signal involving asthma and COPD, and one of the strangest Ozempic access stories of the week. Recorded from the Bask Health Studios. This episode is sponsored by VoaFit. Learn more about VoaFit here: https://voafit.com/otp This episode was filmed in the Bask Health Studios, visit: https://bask.health Follow On The Pen everywhere plus get special discounts: https://otplinks.com Read more at: https://obesity.news

  ListenShow Notes
• 

  On The Pen GLP-1 News

  We’re Solving Obesity. Now Who Pays for It?

  Sep 1, 202625 min

  This week on On The Pen, the GLP-1 story is moving in two very different directions. The Fifth Circuit handed FDA major wins in the fight over semaglutide and tirzepatide shortages, FDA updated its consumer guidance around compounded GLP-1 medications and multi-dose vials, and employers continue questioning whether they can afford obesity-drug coverage. At the same time, the medical case for these medications keeps getting stronger. We break down Mounjaro’s new cardiovascular indication and what preventing heart attacks and strokes could mean for the true long-term cost of GLP-1 treatment. We also look at 600,000 Medicare beneficiaries already enrolling in the $50 GLP-1 Bridge program, California’s effort to tackle affordability, the rapidly expanding oral GLP-1 market, and new real-world data on patients staying at lower doses of semaglutide and tirzepatide. The science is expanding. Access is contracting. And that may be the biggest challenge facing the next phase of the GLP-1 revolution. In this episode: • What the Fifth Circuit compounding decisions actually mean • FDA’s updated language around compounded GLP-1 vials • The 28-day multi-dose vial controversy • Mounjaro’s new cardiovascular indication • Why GLP-1s may reduce long-term healthcare costs • Employers dropping obesity-drug coverage • 600,000 people joining the Medicare GLP-1 Bridge • California’s push for lower GLP-1 prices • The oral GLP-1 race • New data on lower-dose semaglutide and tirzepatide Follow everything On The Pen: This episode is sponsored by VoaFit. https://www.voafit.com/otp This content is for informational and educational purposes only and is not medical advice. Always discuss medication and treatment decisions with a qualified healthcare professional.

  ListenShow Notes

Recent guests on On The Pen GLP-1 News. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.